The objective of the partnership is to automate portions of ScaleReady’s CGT manufacturing workflow by using Cellular Origin’s robotic system for sterile liquid transfer.
Cellular Origins announced its collaborative partnership with ScaleReady on May 11, 2023 to further bring together process development expertise, tools, and technologies for scalable cell and gene therapies (CGT) manufacturing. The objective of the partnership is to automate portions of ScaleReady’s CGT manufacturing workflow by using Cellular Origin’s robotic system for sterile liquid transfer, according to the press release.
The first project in the collaboration will be to standardize and automate interconnections between the modules of ScaleReady’s G-Rex, which is a manufacturing platform used by therapy developers internationally to produce CGTs for clinical trials, including the most recently approved commercial therapies. Further, integrating Cellular Origins’ robotic system will help to eliminate variability in manual connection techniques, the company says. According to the press release, these projects will automate additional areas of ScaleReady’s workflow, like the robotic movement of G-Rex into and out of incubators.
“ScaleReady’s technologies are widely adopted in the production of advanced, cell-based therapies. This collaboration demonstrates the adaptability of our robotic system, highlighting that it can be integrated seamlessly into existing workflows and allowing therapy developers access to scalable, cost-effective advanced therapy manufacture without significant process redevelopment,” said Edwin Stone, PhD, CEO of Cellular Origins, in a press release.
Source: BusinessWire
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
WMFTS’ BioPure to Showcase Single-Use Bioclamp with Refined Manufacturing at INTERPHEX 2025
April 1st 2025With advanced manufacturing, BioPure’s BioClamp connector is manufactured to be 13% lighter than the previous model, resulting in a 26% reduction in carbon dioxide emissions across the full lifecycle of the product.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.